Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on October 2, 2020, covering events occurring on September 30, 2020. The filing discloses the entry into a material definitive agreement regarding office space and the departure of a senior officer.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses on specific contractual obligations and executive compensation arrangements.
Material Changes and Agreements
Real Property Lease Amendment
- Agreement: First Amendment to a non-cancelable lease for office space at 101 Main Street, Cambridge, Massachusetts.
- Scope: Extends the lease term for the 12th and 13th floors by five years, through June 30, 2026. The 16th floor lease remains set to expire on June 30, 2021.
- Rent Terms: Beginning July 2021, annual rent will be $3.54 million for the first twelve months, with 2.0% annual increases thereafter.
- Options: The Company retains an option to extend the amended lease term for an additional five years.
Executive Departure and Compensation
- Resignation: Barry E. Greene resigned as President effective September 30, 2020, after 17 years of service.
- Consulting Role: Mr. Greene will provide consulting services for up to 10 hours per month for two years (through September 30, 2022).
- Compensation Package:
- Cash Compensation: $627,300 paid in bi-weekly installments from October 1, 2020, to September 30, 2021.
- Equity: Continued vesting of all outstanding equity awards through September 30, 2022.
- Health Benefits: Lump sum payment for 18 months of the Company's portion of COBRA premiums.
- 2020 Bonus: $376,380 cash bonus (60% of base salary target), payable in January 2021.
- Restrictions: Non-compete and non-solicitation obligations extended for two years post-resignation.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or new risk factors. It notes that the summaries of the agreements are qualified by reference to the full text, which will be filed as exhibits to the Form 10-Q for the quarter ending September 30, 2020.
Investor Verification Checklist
- Verify the total committed cost of the lease extension, including the $3.54 million starting rent and subsequent 2% annual escalations.
- Confirm the total cash outflow associated with Mr. Greene's departure package ($627,300 consulting + $376,380 bonus + COBRA lump sum).
- Review the upcoming Form 10-Q for the full text of the First Amendment to Lease and the Letter Agreement with Mr. Greene.
- Assess the operational impact of the 16th floor lease expiring in June 2021 versus the extended terms for the 12th and 13th floors.